 |
|
|
|
home / press room / news and events / news
 News
September 01, 2011
Thermo Fisher Scientific acquires Intrinsic Bioprobes Inc.
Rochester, NY, September 01, 2011 – Thermo Fisher Scientific today announced the acquisition of Intrinsic Bioprobes Inc. The Intrinsic Bioprobes portfolio enables Thermo Fisher to offer its worldwide life science research and clinical diagnostics customers an enhanced solution for quantitative protein biomarker detection.
For the full text of this press release, please click here .
April 19, 2011
Intrinsic Bioprobes launches three new CLIA approved mass spectrometry-based tests for proteins implicated in kidney disease and renal failure
Tempe, AZ, April 19, 2011 – Intrinsic Bioprobes Inc (“IBI”) today announced the launch of its first mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI’s MASSAY® platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.
For the full text of this press release, please click here .
July 15, 2010
Thermo Fisher Scientific and Intrinsic Bioprobes Announce Alliance in Mass Spectrometric Immunoassay (MSIA) Workflow Development
Tempe, AZ, July 15, 2010 – Thermo Fisher Scientific Inc., and Intrinsic Bioprobes (IBI) Inc., announce an alliance to co-develop and market a mass spectrometry solution that will enable researchers to perform quantitative, high-throughput, high-resolution protein biomarker assays. The solution couples the specificity of immunoenrichment with the sensitivity and quantitative capability of mass spectrometry to provide researchers with a more complete, higher-resolution view of the proteome. Initially, via an exclusive reseller agreement, the solution will be applied to the detection of human parathyroid hormone (PTH) and its variants, which may be useful as biomarkers for bone diseases and diseases of the endocrine system.
For the full text of this press release, please click here .
January 21, 2010
Intrinsic Bioprobes announces the discovery and exclusive licensing of novel biomarkers for diabetes
Tempe, AZ, January 21, 2010 – Intrinsic Bioprobes today announced the exclusive licensing of two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, Inc. (Raritan, NJ). The biomarkers are modified forms of blood-circulating proteins and have been linked with the presence of pre-diabetes and type 2 diabetes.
For the full text of this press release, please click here .
March 31, 2009
Intrinsic Bioprobes Inc. enters into a $1.27M contract with the National Cancer Institute to develop Multiplex Mass Spectrometric Immunoassays for detection of low abundance cancer related proteins
Tempe, AZ March 31, 2009 –Intrinsic Bioprobes Inc. today announced the start of a contract with the National Cancer Institute to develop effective technologies for accurate measurement of cancer related proteins and
peptides that improve diagnostic capabilities by effectively discerning diseased from non-diseased states. This contract is in support of NCI’s Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research.
For the full text of this press release, please click here .
October 16 , 2008
Intrinsic Bioprobes develops novel mass spectrometry-based assay that reveals degradation and low levels of bioactive B-type Natriuretic Peptide (BNP) in patients with heart failure
Tempe, AZ October 16. A team of researchers from Intrinsic Bioprobes Inc. has reported on a novel quantitative mass spectrometry immunoassay for the detection of bioactive B-type natriuretic
peptide (BNP), in an article published online on Oct. 14 in the journal of Circulation: Heart Failure. In collaboration with colleagues from Scios Inc. in Fremont, Christ Hospital in Cincinnati, and Medivation Inc. in San
Francisco, the team discovered very low concentration of bioactive BNP in plasma obtained from patients with heart failure, and presented direct structural evidence for several proteolytically degraded forms of BNP in
these patients.
For the full text of this press release, please click here .
|
|
 |
|
|
